Join Drs. Kotton, Pereira, and Razonable as they discuss the management of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. Topics covered include treatment challenges, laboratory testing, and new therapy for refractory or resistant CMV.
Upon completion of this activity, participants should be better able to:
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Associate Professor, Medicine
Harvard Medical School
Boston, MA
Associate Professor, Medicine
Medical Director, Transplant Infectious Diseases Program
Columbia University Irving Medical Center
NewYork Presbyterian Hospital
New York, NY
Professor, Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, MN
Resources
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Camille Nelson Kotton, MD, FIDSA, FAST, has relevant financial relationships with Abbott Laboratories, Biotest, Evrys, Exevir, Hookipa, Merck, Oxford Immunotec, QIAGEN, Roche Diagnostics, Takeda (Consultant).
Marcus R. Pereira, MD, MPH, FAST, has relevant financial relationships with Takeda (Consultant).
Raymund R. Razonable, MD, FIDSA, FAST, has relevant financial relationships with Gilead, Regeneron, Roche (Grant/Research Support); Merck (Other: Data Adjudication Committee).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-23-007-H01-P)
Type of Activity: Knowledge
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
Users must:
There is no fee to participate.
In order to claim MOC points, users must:
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
